STAAR Surgical Company (STAA) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.008x

Based on the latest financial reports, STAAR Surgical Company (STAA) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.67 Million) by net assets ($353.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

STAAR Surgical Company - Cash Flow Conversion Efficiency Trend (1990–2024)

This chart illustrates how STAAR Surgical Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read STAAR Surgical Company total liabilities for a breakdown of total debt and financial obligations.

STAAR Surgical Company Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of STAAR Surgical Company ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Ji'an Mankun Technology Co. Ltd. A
SHE:301132
0.015x
Beingmate Baby & Child Food Co Ltd
SHE:002570
0.012x
CSBC Corp Taiwan
TW:2208
-0.528x
Tejas Networks Limited
NSE:TEJASNET
-0.154x
SAF Holland SA
XETRA:SFQ
0.157x
Storytel AB (publ)
ST:STORY-B
0.099x
Playtech plc
F:PL8
0.074x
Regional Container Lines Public Company Limited
BK:RCL
0.053x

Annual Cash Flow Conversion Efficiency for STAAR Surgical Company (1990–2024)

The table below shows the annual cash flow conversion efficiency of STAAR Surgical Company from 1990 to 2024. For the full company profile with market capitalisation and key ratios, see how much is STAAR Surgical Company worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $397.33 Million $15.72 Million 0.040x +4.66%
2023-12-31 $385.95 Million $14.59 Million 0.038x -64.41%
2022-12-31 $336.11 Million $35.72 Million 0.106x -37.50%
2021-12-31 $258.56 Million $43.96 Million 0.170x +60.06%
2020-12-31 $197.22 Million $20.95 Million 0.106x -34.16%
2019-12-31 $159.88 Million $25.80 Million 0.161x +67.35%
2018-12-31 $132.43 Million $12.77 Million 0.096x +45.09%
2017-12-31 $42.94 Million $2.85 Million 0.066x +140.10%
2016-12-31 $37.91 Million $1.05 Million 0.028x +149.72%
2015-12-31 $38.85 Million $-2.16 Million -0.056x +74.03%
2014-12-31 $37.10 Million $-7.95 Million -0.214x -348.41%
2013-12-31 $38.85 Million $3.35 Million 0.086x -14.87%
2012-12-31 $31.74 Million $3.22 Million 0.101x -44.15%
2011-12-31 $29.46 Million $5.35 Million 0.181x +192.14%
2010-12-31 $22.43 Million $-4.42 Million -0.197x -390.80%
2009-12-31 $21.07 Million $1.43 Million 0.068x +113.19%
2008-12-31 $16.03 Million $-8.23 Million -0.513x -66.29%
2007-12-31 $36.23 Million $-11.18 Million -0.309x -13.40%
2006-12-31 $31.76 Million $-8.65 Million -0.272x -57.54%
2005-12-31 $40.37 Million $-6.98 Million -0.173x +25.68%
2004-12-31 $37.86 Million $-8.80 Million -0.233x -98.67%
2003-12-31 $35.42 Million $-4.15 Million -0.117x -730.49%
2002-12-31 $30.65 Million $569.00K 0.019x +133.98%
2001-12-31 $46.83 Million $-2.56 Million -0.055x +40.35%
2000-12-31 $58.67 Million $-5.37 Million -0.092x -199.42%
1999-12-31 $53.20 Million $4.90 Million 0.092x +4.10%
1998-12-31 $48.60 Million $4.30 Million 0.088x -47.84%
1997-12-31 $44.80 Million $7.60 Million 0.170x -26.95%
1996-12-31 $36.60 Million $8.50 Million 0.232x +33.31%
1995-12-31 $28.70 Million $5.00 Million 0.174x -4.18%
1994-12-31 $22.00 Million $4.00 Million 0.182x +318.18%
1993-12-31 $12.00 Million $-1.00 Million -0.083x +80.38%
1992-12-31 $7.30 Million $-3.10 Million -0.425x +62.73%
1991-12-31 $4.30 Million $-4.90 Million -1.140x -13.95%
1990-12-31 $100.00K $-100.00K -1.000x --

About STAAR Surgical Company

NASDAQ:STAA USA Medical Instruments & Supplies
Market Cap
$1.34 Billion
Market Cap Rank
#10195 Global
#2585 in USA
Share Price
$27.19
Change (1 day)
+3.15%
52-Week Range
$16.10 - $28.57
All Time High
$162.68
About

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serve… Read more